{"nctId":"NCT00249795","briefTitle":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","startDateStruct":{"date":"2003-06"},"conditions":["Atrial Fibrillation","Cardiovascular Disease"],"count":9016,"armGroups":[{"label":"Irbesartan","type":"EXPERIMENTAL","interventionNames":["Drug: Irbesartan"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Irbesartan","otherNames":["AprovelÂ®"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nShould fulfill the eligibility criteria for ACTIVE A or ACTIVE W trial and:\n\n* have a systolic blood pressure of at least 110 mmHg\n* not already receiving an angiotensin receptor blocking agent, unless they are willing and able to be changed to another antihypertensive agent\n* no previous intolerance to angiotensin receptor blocking agents\n* no proven indication for angiotensin receptor blocking agents, unless an Angiotensin Converting Enzyme (ACE) inhibitor can be substituted\n\nExclusion Criteria:\n\nPatients will be excluded from ACTIVE study if any of the following are present:\n\n* requirement for clopidogrel (such as recent coronary stent procedure)\n* requirement for oral anticoagulant (such as prosthetic mechanical heart valve)\n* prior intolerance to acetylsalicyclic acid (ASA) or clopidogrel\n* documented peptic ulcer disease within the previous 6 months\n* prior intracerebral hemorrhage\n* significant thrombocytopenia (platelet count \\<50 x 10(9)/L)\n* psychosocial reason making study participation impractical\n* geographic reason making study participation impractical\n* ongoing alcohol abuse\n* mitral stenosis\n* pregnant or nursing woman or woman of child bearing potential and not on effective birth control for at least one month prior to start of study or not willing to continue on birth control for duration of study\n* severe comorbid condition such that the patient is not expected to survive 6 months\n* patient currently receiving an investigational pharmacologic agent\n* requirement for chronic (\\> 3 months) non-cyclooxygenase-2 (non-COX-2) inhibitor nonsteroidal anti-inflammatory drug (NSAID) therapy unless willing enrolled in ACTIVE A","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication","description":"The first co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal) or vascular death - after validation by the Event Adjudication Committee (EAC).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"963","spread":null},{"groupId":"OG001","value":"963","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":null},{"groupId":"OG001","value":"407","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"460","spread":null},{"groupId":"OG001","value":"433","spread":null}]}]}]},{"type":"PRIMARY","title":"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke, Vascular Death or Hospitalization for Heart Failure as Per Adjudication","description":"The second co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal), vascular death or hospitalization for heart failure - after validation by the EAC.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1236","spread":null},{"groupId":"OG001","value":"1291","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null},{"groupId":"OG001","value":"375","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"331","spread":null},{"groupId":"OG001","value":"291","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"443","spread":null},{"groupId":"OG001","value":"513","spread":null}]}]}]},{"type":"SECONDARY","title":"First Occurrence of Stroke","description":"The considered event is the first occurrence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) over the duration of follow-up, after validation by the EAC.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"411","spread":null}]}]}]},{"type":"SECONDARY","title":"Death From Any Cause","description":"The considered event is the death over the duration of the follow-up whatever the cause, cardiovascular or non-cardiovascular.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"949","spread":null},{"groupId":"OG001","value":"929","spread":null}]}]}]},{"type":"SECONDARY","title":"First Occurrence of Any Heart Failure (HF) Episode","description":"The considered event is the first occurence of any HF episode defined as evidence of signs and symptoms of HF with or without hospitalization over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"699","spread":null},{"groupId":"OG001","value":"767","spread":null}]}]}]},{"type":"SECONDARY","title":"First Hospitalisation for Heart Failure (HF)","description":"The considered event is the first overnight hospital stay for HF over the duration of the follow-up, after validation by the EAC.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"482","spread":null},{"groupId":"OG001","value":"551","spread":null}]}]}]},{"type":"SECONDARY","title":"First Hospitalisation for Other Cardiovascular (CV) Cause","description":"The considered event is the overnight hospital stay for any CV cause other than Heart Failure over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1186","spread":null},{"groupId":"OG001","value":"1174","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1409,"n":4518},"commonTop":["Any infections and infestations","Any gastrointestinal disorders","Any nervous system disorders","Any musculoskeletal and connective tissue disorders","Any general disorders and administration site conditions"]}}}